Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA’s Poor Performance ‘Invites Catastrophe’ – U.S. Congressional Committee On Heparin Investigation

This article was originally published in PharmAsia News

Executive Summary

The House Energy & Commerce Subcommittee on Oversight and Investigations simultaneously lauded and criticized U.S. FDA's handling of the heparin contaminant safety issue, which FDA now says was most likely the result of intentional actions

You may also be interested in...



FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China

SAN FRANCISCO - U.S. FDA's newly launched China office is still developing protocols for the country, and the agency is considering adding the use of unannounced inspections to its arsenal of tools crafted to improve product safety and quality

FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China

SAN FRANCISCO - U.S. FDA's newly launched China office is still developing protocols for the country, and the agency is considering adding the use of unannounced inspections to its arsenal of tools crafted to improve product safety and quality

FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China

FDA already has conducted such inspections in India since opening an office there.

Related Content

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel